FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-02									

OMB Number:	3235-028
Estimated average bu	ırden
hours per response:	0

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER					2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /								Relationship of Reporting Person(s) to Issuer (Check all applicable)						
(Last)	(F	irst)		MA [VRTX]								X	below)	(give title	v.& F	10% Ov Other (s below) Realiz, CS	specify		
C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET					09/	3. Date of Earliest Transaction (Month/Day/Year) 09/17/2008													
(Street) CAMBRIDGE MA 02139					_ 4. II	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(S	-	(Zip)																
			le I - N			_			· ·	d, D	isposed o	-							
Date				2. Transac Date (Month/Da		Year) Execu		Deemed cution Date, y nth/Day/Year)				es Acquired (A) or Of (D) (Instr. 3, 4 an		Benefic Owned		ies Fo cially (D Following (I)		: Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3		tion(s)			(Instr. 4)
Common Stock 09/17/20					2008	8			M		2,400	A	\$9.07	88,7		,790		D	
Common Stock 09/17/20					2008	8		S ⁽¹⁾		2,400	D	\$27.94(2	(2)(3) 86		6,390		D		
Common Stock															3,460		I	401(k)	
		7	able I								posed of , converti			y Ow	ned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Securi (Instr. 3 and 4)		8. Price o Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercis	sable	Expiration Date	Title	Amount or Number of Shares	er					
Stock	\$9.07	09/17/2008			М			2,400	(4)		12/10/2013	Commor	2,400	9	BO	0 9.600		D	1

Explanation of Responses:

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Mueller's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Open market sales reported on this line occurred at a weighted average price of \$27.94 (range \$27.46 to \$28.40).
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

Remarks:

Valerie L. Andrews, Attorney-

09/19/2008

In-Fact

** Signature of Reporting Person

Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.